NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock
NurExone Biologic has been named to the 2025 TSX Venture 50™, a prestigious ranking of top-performing companies on the TSX Venture Exchange. The company stands out as the only biotech firm among three life sciences companies receiving this recognition, demonstrating its leadership in exosome-based therapies and regenerative medicine for central nervous system injuries.
The company achieved remarkable performance metrics, including 110% share price appreciation and 209% market cap growth. The TSX Venture 50™ selection process evaluated 1,605 listed issuers, with chosen companies showing exceptional performance across various metrics. In 2024, the selected companies averaged 207% share price appreciation.
Key achievements include progress in developing ExoPTEN, their proprietary exosome therapy for acute spinal cord injuries, and establishing U.S. subsidiary Exo-Top Inc. to enhance exosome production capabilities. The TSXV platform serves as a important foundation for early-stage, high-growth companies, with 80% of 2024's Venture 50™ companies operating internationally.
NurExone Biologic è stata nominata tra le 50 migliori aziende del TSX Venture 2025™, un prestigioso riconoscimento per le aziende che si sono distinte sul TSX Venture Exchange. L'azienda si distingue come l'unica azienda biotech tra tre aziende delle scienze della vita a ricevere questo riconoscimento, dimostrando la sua leadership nelle terapie basate sugli esosomi e nella medicina rigenerativa per le lesioni del sistema nervoso centrale.
L'azienda ha ottenuto metriche di performance straordinarie, tra cui un aumento del 110% del prezzo delle azioni e una crescita del 209% della capitalizzazione di mercato. Il processo di selezione per le 50 migliori aziende del TSX Venture™ ha valutato 1.605 emittenti quotati, con le aziende scelte che hanno mostrato performance eccezionali in vari parametri. Nel 2024, le aziende selezionate hanno registrato una media del 207% di apprezzamento del prezzo delle azioni.
I risultati chiave includono progressi nello sviluppo di ExoPTEN, la loro terapia proprietaria a base di esosomi per lesioni acute del midollo spinale, e l'istituzione della sussidiaria americana Exo-Top Inc. per migliorare le capacità di produzione di esosomi. La piattaforma TSXV funge da fondamentale base per aziende in fase iniziale e ad alta crescita, con l'80% delle aziende del Venture 50™ del 2024 che operano a livello internazionale.
NurExone Biologic ha sido nombrada entre las 50 mejores empresas del TSX Venture 2025™, un prestigioso ranking de las empresas de mejor rendimiento en el TSX Venture Exchange. La compañía se destaca como la única firma biotecnológica entre tres empresas de ciencias de la vida que reciben este reconocimiento, demostrando su liderazgo en terapias basadas en exosomas y medicina regenerativa para lesiones del sistema nervioso central.
La empresa logró métricas de rendimiento notables, incluyendo un incremento del 110% en el precio de las acciones y un crecimiento del 209% en la capitalización de mercado. El proceso de selección de las 50 mejores empresas del TSX Venture™ evaluó a 1,605 emisores listados, con las empresas elegidas mostrando un rendimiento excepcional en diversas métricas. En 2024, las empresas seleccionadas promediaron un 207% de apreciación en el precio de las acciones.
Los logros clave incluyen avances en el desarrollo de ExoPTEN, su terapia propietaria a base de exosomas para lesiones agudas de la médula espinal, y el establecimiento de la subsidiaria estadounidense Exo-Top Inc. para mejorar las capacidades de producción de exosomas. La plataforma TSXV sirve como una base importante para empresas en etapas tempranas y de alto crecimiento, con el 80% de las empresas del Venture 50™ de 2024 operando internacionalmente.
NurExone Biologic는 2025년 TSX 벤처 50™에 선정되었습니다. 이는 TSX 벤처 거래소에서 성과가 뛰어난 회사들에 대한 권위 있는 순위입니다. 이 회사는 이 인정을 받은 세 개의 생명 과학 회사 중 유일한 생명공학 회사로, 엑소좀 기반 치료법 및 중추 신경계 손상을 위한 재생 의학에서의 리더십을 입증하고 있습니다.
회사는 주가 110% 상승 및 209% 시장 가치 성장을 포함한 놀라운 성과 지표를 달성했습니다. TSX 벤처 50™ 선정 과정은 1,605개의 상장 발행사를 평가했으며, 선택된 회사들은 다양한 지표에서 뛰어난 성과를 보였습니다. 2024년에는 선정된 회사들이 평균 207%의 주가 상승률을 기록했습니다.
주요 성과로는 급성 척수 손상을 위한 그들의 독점 엑소좀 치료제인 ExoPTEN 개발의 진전과 엑소좀 생산 능력을 향상시키기 위해 미국 자회사 Exo-Top Inc.를 설립한 것이 포함됩니다. TSXV 플랫폼은 초기 단계의 고성장 기업을 위한 중요한 기반 역할을 하며, 2024년 벤처 50™ 기업의 80%가 국제적으로 운영되고 있습니다.
NurExone Biologic a été classée parmi les 50 meilleures entreprises du TSX Venture 2025™, un classement prestigieux des entreprises les plus performantes sur le TSX Venture Exchange. L'entreprise se distingue comme la seule société biopharmaceutique parmi trois entreprises des sciences de la vie à recevoir cette reconnaissance, démontrant son leadership dans les thérapies basées sur les exosomes et la médecine régénérative pour les blessures du système nerveux central.
L'entreprise a réalisé des performances remarquables, y compris une augmentation de 110% du prix des actions et une croissance de 209% de la capitalisation boursière. Le processus de sélection des 50 meilleures entreprises du TSX Venture™ a évalué 1 605 émetteurs cotés, les entreprises choisies montrant des performances exceptionnelles sur divers indicateurs. En 2024, les entreprises sélectionnées ont enregistré une moyenne de 207% d'appréciation du prix des actions.
Les réalisations clés incluent des progrès dans le développement de ExoPTEN, leur thérapie à base d'exosomes pour les lésions aiguës de la moelle épinière, et l'établissement de la filiale américaine Exo-Top Inc. pour améliorer les capacités de production d'exosomes. La plateforme TSXV sert de base importante pour les entreprises en phase de démarrage et à forte croissance, avec 80% des entreprises du Venture 50™ de 2024 opérant à l'international.
NurExone Biologic wurde in die Liste der 50 besten Unternehmen des TSX Venture 2025™ aufgenommen, eine prestigeträchtige Rangliste der leistungsstärksten Unternehmen an der TSX Venture Exchange. Das Unternehmen hebt sich als einziges Biotech-Unternehmen unter drei Unternehmen der Lebenswissenschaften hervor, die diese Auszeichnung erhalten haben, und zeigt damit seine Führungsrolle in exosom-basierten Therapien und regenerativer Medizin bei Verletzungen des zentralen Nervensystems.
Das Unternehmen erzielte bemerkenswerte Leistungskennzahlen, darunter eine Wertsteigerung des Aktienkurses um 110% und ein Marktkapitalwachstum von 209%. Der Auswahlprozess für die TSX Venture 50™ bewertete 1.605 gelistete Emittenten, wobei die ausgewählten Unternehmen außergewöhnliche Leistungen in verschiedenen Kennzahlen zeigten. Im Jahr 2024 betrug die durchschnittliche Wertsteigerung des Aktienkurses der ausgewählten Unternehmen 207%.
Wichtige Erfolge umfassen Fortschritte bei der Entwicklung von ExoPTEN, ihrer proprietären Exosomtherapie für akute Rückenmarksverletzungen, sowie die Gründung der US-Tochtergesellschaft Exo-Top Inc., um die Produktionskapazitäten für Exosomen zu verbessern. Die TSXV-Plattform dient als wichtige Grundlage für Unternehmen in der Frühphase mit hohem Wachstum, wobei 80% der Unternehmen des Venture 50™ im Jahr 2024 international tätig sind.
- None.
- None.
TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025 TSX Venture 50™, a prestigious annual ranking of the top-performing companies on the TSX Venture Exchange (“TSXV”). NurExone is honored to be the only biotech company, and one of three life sciences companies, to receive this designation, highlighting NurExone’s leadership in the emerging field of exosome-based therapies and regenerative medicine for central nervous system injuries. This recognition also highlights NurExone’s strong market performance and strategic advances in the past year including
The TSX Venture 50™ recognizes the top 50 performing issuers out of the 1,605i listed issuers on the TSXV, across all sectors. Each company recognized is evaluated and chosen based on a combination of metrics including one year share price appreciation and market capitalization growth. In 2024, the 50 selected companies delivered an impressive average share price appreciation of
“We are deeply honored to be recognized as a TSX Venture 50™ company. This reflects our unwavering commitment to advancing exosome-based therapies and creating long-term value for our shareholders,” said Dr. Lior Shaltiel, CEO of NurExone. “It’s a testament to the growing investor confidence in our mission to revolutionize regenerative medicine, the strength of our scientific breakthroughs, and the dedication of our talented team.”
Key milestones driving NurExone’s success include significant progress in the development of ExoPTEN, the Company’s proprietary exosome therapy for acute spinal cord injuries, as well as NurExone’s establishment of its U.S. subsidiary, Exo-Top Inc., which accelerates its exosome production capabilities and advancement of their clinical pipeline. These efforts will help position NurExone as a leader in the rapidly growing field of exosome-based therapies.
The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024,
Yoram Drucker, Chairman of NurExone, added “being recognized by the TSX Venture 50™ is a significant milestone for NurExone, highlighting our strong financial performance and growth trajectory. We look forward to continuing our success as we expand our presence in the U.S. and explore new listing opportunities.”
About NurExone
NurExone Biologic Inc. is a TSXV, OTCQB and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsiv. Regulatory milestones, including Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Oak Hill Financial Inc.
2 Bloor Street, Suite 2900
Toronto, Ontario M4W 3E2
Investor Relations – Canada
Phone: +1-647-479-5803
Email: info@oakhillfinancial.ca
Dr. Eva Reuter
Investor Relations – Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
Allele Capital Partners
Investor Relations – U.S.
Phone: +1 978-857-5075
Email: aeriksen@allelecapital.com
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the Company’s advancing exosome-based therapies and creating long term value for shareholders; growing investor confidence in the Company’s mission; Exo-Top Inc. accelerating its exosome production capabilities and advancing its clinical pipeline; the Company becoming a leader in the field of exosome-based therapies; the continued success of the Company; the Company expanding its presence in the U.S. and exploring new listing opportunities; the Company completing clinical trials in the U.S. and Europe; the Company’s future plans and expectations; growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone advancing its development pipeline; NurExone’s focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology offering solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company will advance exosome-based therapies and create long term value for shareholders; there being growing investor confidence in the Company’s mission; Exo-Top Inc. will accelerate its exosome production capabilities and advance its clinical pipeline; the Company will become a leader in the field of exosome-based therapies; the Company will continue to succeed; the Company will expand its presence in the U.S. and explore new listing opportunities; the Company will complete clinical trials in the U.S. and Europe; there will be growing clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas; NurExone will advance its development pipeline; NurExone will continue to focus on developing regenerative exosome-based therapies for central nervous system injuries; and the NurExone platform technology will offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel, and on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company’s products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; the Company’s inability to expand into further studies; Exo-Top not have the intended benefits on the Company and/or its business; the Company be unable to advance exosome-based therapies and/or create long term value for shareholders; investor confidence in the Company’s mission deteriorating; the Company not becoming a leader in the field of exosome-based therapies; the Company being unable to expand its presence in the U.S. and/or explore new listing opportunities; the Company being unable to initiate and/or complete clinical trials in the U.S. and Europe; clinical demand for innovative treatments in spinal cord, optic nerve, and other therapeutic areas deteriorating; NurExone being unable to advance its development pipeline; NurExone being unable to focus on developing regenerative exosome-based therapies for central nervous system injuries; the NurExone platform technology being unable to offer solutions to companies interested in quality exosomes and/or minimally invasive targeted delivery systems for other indications; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s annual information form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
_____________________
i TMX
ii https://money.tmx.com/en/venture50
iii https://money.tmx.com/en/venture50
iv Spinal cord injury, Glaucoma
FAQ
What performance metrics earned NRXBF a spot in the 2025 TSX Venture 50™?
How many biotech companies were included in the 2025 TSX Venture 50™?
What is NurExone's main therapeutic product in development?
What strategic expansion did NRXBF make in the US market?
What was the average share price appreciation for TSX Venture 50™ companies in 2024?
